Charles Legg is Zea's interim CEO, and COO. He oversees Zea's global operations and execution of our strategic initiatives. In addition, he leads Zea’s advanced development team to build out Zea’s Lighthouse Platform, our next-generation system for therapeutics development. Charles is also dedicated to moving quickly on our prioritized portfolio and building our culture of open communication and accountability to provide our employees with the motivation and vision to enable the best outcomes possible for patients worldwide.
Charles joined Zea after successfully serving as Chief Operating Officer for a clinical-stage biotechnology company, CureLab Oncology. Before CureLab, he was VP of N. American Operations for Clinithink, a company leveraging Artificial Intelligence. Charles is an entrepreneur at heart and has worked with various exciting startups, including bluebird bio (gene and cellular therapies), Solid Biosciences (gene therapy), both of which enjoyed large IPOs and several other earlier stage companies. He also enjoyed a significant career-building time at Shire, later acquired by Takeda. In addition, he had ascending roles in Program & Portfolio Management, working on various therapeutic development teams and early, middle, and late-stage/commercial launches.
Charles holds a B.A. in Biology (concentration: Cell & Molecular Biology/Biochemistry) and serves on several BODs, both professional and non-profit.